HQH
Abrdn Healthcare Investors18.80
-0.20-1.05%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.04BP/E (TTM)
11.68Basic EPS (TTM)
1.61Dividend Yield
0.12%Recent Filings
8-K
Auditor resignation and switch
Tekla Healthcare Investors' auditor Deloitte & Touche resigned on September 6, 2023, due to an independence issue from a pending transaction between Tekla Capital Management and abrdn Inc., with the Audit Committee approving it the next day. The Board then engaged KPMG as the new auditor for the fiscal year ending September 30, 2023. No disagreements or reportable events marred Deloitte's prior audits. This switch ensures compliance amid ownership changes.
8-K
HQH renews buyback program
H&Q Healthcare Investors renewed its share repurchase program on March 22, 2013, authorizing open-market buys of up to 12% of outstanding common shares through July 10, 2014. This move aims to boost net asset value per share and narrow the market price discount to NAV, while enhancing trading liquidity. Repurchases hinge on adviser discretion. No guarantees of price gains.
8-K
HQH renews 12% share buyback
H&Q Healthcare Investors renewed its share repurchase program on March 23, 2012, authorizing open-market buys of up to 12% of outstanding common shares over the next year starting July 11. This move aims to boost net asset value per share and narrow the market price discount to NAV, while enhancing trading liquidity. Repurchases hinge on adviser discretion; outcomes remain uncertain. The board will track impacts on expenses and strategy.
8-K
Shareholders approve trust amendment
8-K
Share repurchase program authorized
H&Q Healthcare Investors announced a share repurchase program on June 30, 2011, authorizing the buyback of up to 12% of its outstanding common shares in the open market over one year starting July 11, 2011. The move aims to enhance shareholder value by narrowing the discount to net asset value per share while boosting liquidity. Repurchases, at the adviser's discretion, will be disclosed in shareholder reports. No guarantees exist on price impacts.
AEF
27762
6.78-0.11
AGD
"abrdn Global Dynamic Dividend
11.43+0.00
AOD
Aberdeen Total Dynamic Dividend
9.64-0.07
BME
Blackrock Health Sciences Trust
40.60-0.47
HEQ
John Hancock Hedged Equity & In
10.72-0.01
HQL
TeklaLife Sciences Investors
16.81-0.23
IAF
61617
13.06+0.27
JEQ
Aberdeen Japan Equity Fund, Inc
8.05-0.24
THQ
Tekla Healthcare Opportunies Fu
18.67-0.26
THW
Tekla World Healthcare Fund Sha
12.42-0.21